August 29, 2022: FDA warns “Tramadol US” to stop selling controlled, unapproved drugs to U.S. residents - safemedicines.org
FDA warns 'Tramadol US' to stop selling controlled, unapproved drugs to U.S. residents.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 29, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, especially those involved in controlled substances and unapproved drugs. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately, as the warning indicates ongoing enforcement action.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a warning to 'Tramadol US' for selling controlled, unapproved drugs to U.S. residents.
Who it affects
All pharmaceutical manufacturers, especially those involved in controlled substances and unapproved drugs.
What you must do
Review your product portfolio to ensure all drugs are FDA-approved and comply with controlled substance regulations; cease sale of any unapproved drugs.
Deadline
Immediately, as the warning indicates ongoing enforcement action.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Balance of Nature ordered to stop selling supplements - cspi.org
- Texas outsourcer in Lilly's compounded tirzepatide lawsuit hit with FDA warning letter - fiercepharma.com
- CONCORD – An Arizona company and CEO pleaded guilty today in federal - fda.gov
- Outsourcing Facility Fee Rates for Fiscal Year 2027
- Over-the-Counter Monograph Drug User Fee Rates for Fiscal Year 2027